| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Accuray Incorporated$0.34
+0 (+0.63%)
D 24Pipeline Score MedTech · Clinical
Market Cap
47.37 M
EPS
-0.38
P/E Ratio
-1.05 $
Value Trade
453.88 K
SEC Financials
Q1 2026Dilution Risk
50%Revenue
104.84 M
R&D Expenses
8.18 M
Total Assets
447.60 M
Total Liabilities
405.89 M
Equity
41.71 M
D/E Ratio
12,345
7.68 %
Week
-27.1 %
1 Month
-44.8 %
3 Month
-67.35 %
6 Month
-93.2 %
5 Year
-98.54 %
All Time
Cash Data
Cash Position
38.07 M
Monthly Burn
3.03 M
Runway
11.5 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
168.43 K
52 Week Range
0.25 - 2.10
% held by Insiders
4.81 %
% held by Institutions
55.45 %
Enterprise Value
191.23 M
Total Shares
118.96 M
Short %
8.25 %
Float Shares
98.15 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D24
Pipeline Score $6M
Pipeline ValueValuation Signal
2
Drugs Scored0.1x
rNPV / MCap Top 24%
Micro Cap (rank 689 of 905)
Percentile RankAccuray Incorporated faces pipeline headwinds (24/100), with $270M risk-adjusted pipeline value, led by Nivolumab in Metastatic Malignant Neoplasm in the Brain (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab Monoclonal antibody | Metastatic Malignant Neoplasm in the Brain | Phase 1 | NCT02716948 | 17% | $254M | COMPLETED | 17 | - | - | Aug 27, 2021 | - | Nov 30, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARAY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ARAY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARAY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARAY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARAY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ARAY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARAYAccuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Accuray Incorporated and the University of Wisconsin-Madison have entered a 10-year strategic collaboration to enhance personalized cancer treatments using Accuray's adaptive radiation therapy platform. This partnership aims to advance clinical research, education, and the development of innovative therapies, building on a successful history of collaboration in radiation medicine. The agreement seeks to improve patient care by leveraging both organizations' strengths.
Read more →ARAYAccuray Reports Fiscal 2026 Third Quarter Financial Results
Accuray Incorporated reported its third quarter financial results for fiscal 2026, revealing a 7% decrease in total net revenue compared to the previous year. The company has made progress with its transformation plan, achieving $10 million in cost improvements. However, geopolitical uncertainties have led to the withdrawal of its financial guidance, impacting product shipments and service revenues. The net loss for the quarter increased to $11.8 million.
Read more →ARAYAccuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray Incorporated will announce its financial results for the third quarter of fiscal 2026 on May 6, 2026. The conference call will be hosted by company management and will include options for both live participation and replay. Accuray emphasizes its commitment to innovation in radiation therapy, aiming to enhance patient care.
Read more →ARAYAccuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele, who has extensive experience in global commercial leadership, will oversee Accuray's global commercialization strategy. His appointment is expected to enhance the company's commercial performance and drive growth in systems and services sales.
Read more →ARAYAccuray Reports Fiscal 2026 Second Quarter Financial Results
Accuray Incorporated reported its fiscal 2026 second quarter results, revealing a 12% decline in total net revenue to $102.2 million. Despite a 4% increase in service revenue, product revenue fell by 26%. The company is undergoing a transformation aimed at enhancing growth and profitability, with CEO Steve La Neve expressing confidence in the strategic changes being implemented.
Read more →ARAYAccuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated will announce its financial results for the second quarter of fiscal 2026 on February 4, 2026. The results will be discussed during a conference call at 1:30 p.m. PT. Investors can access the call via dial-in numbers or a live webcast. A replay will be available for one week after the call.
Read more →ARAYAccuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Accuray Incorporated has announced the first phase of its strategic transformation plan, aiming to enhance operational efficiency and accountability. This initiative is projected to improve annualized operating profitability by around $25 million. The plan includes workforce reductions and restructuring costs, with full implementation expected by the end of fiscal 2026. Accuray maintains its forecasts for the fiscal year despite these changes.
Read more →ARAYAccuray Reports Fiscal 2026 First Quarter Financial Results
Accuray Incorporated reported its fiscal 2026 first quarter financial results, showing a 7% decrease in total net revenue to $93.9 million. Despite a decline in product revenue, the company noted growth in service revenue and ongoing expansion of its CyberKnife and Radixact systems. The net loss widened significantly compared to the previous year, prompting the company to reaffirm its financial guidance for the year.
Read more →ARAYAccuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray Incorporated has granted inducement awards to its new CEO, Stephen La Neve, as part of his employment agreement. The awards include 1.5 million restricted stock units and 1.5 million performance-based restricted stock units, with vesting contingent on stock price performance over the next six years. This move reflects the company's strategy to align executive compensation with long-term shareholder value.
Read more →ARAYAccuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
Accuray Incorporated will announce its first quarter fiscal 2026 financial results on November 5, 2025. The results will be discussed during a conference call at 1:30 p.m. PT/4:30 p.m. ET. A live webcast will also be available, along with a replay for those unable to attend the live event.
Read more →ARAYAccuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
Accuray Incorporated has announced a significant transformation plan, appointing Steve La Neve as CEO to enhance operational performance and competitiveness. The company aims to increase margins and agility while continuing innovation in radiation therapy. The Board has also appointed Steven F. Mayer as Transformation Board Sponsor and nominated Chan W. Galbato to the Board. Preliminary financial results for Q1 2026 show mixed performance, with service revenues exceeding expectations but product revenues falling short.
Read more →ARAYAccuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
Accuray Incorporated has announced the successful treatment of the first patients in Melbourne, Australia, using the CyberKnife S7 System. This initiative, in partnership with 5D Clinics and Icon Group, aims to enhance access to advanced radiation therapy for cancer patients. The new center marks a significant step in improving cancer care and patient outcomes in the region.
Read more →ARAYAccuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
Accuray and the University of Wisconsin-Madison have signed a memorandum of understanding to advance online adaptive radiotherapy (OART). This collaboration focuses on clinical research, education, and technology development to enhance cancer care. Both parties aim to leverage their strengths to improve treatment personalization and precision for patients.
Read more →ARAYAccuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
Accuray has launched the Accuray Stellar solution, an advanced adaptive radiotherapy system designed to enhance cancer treatment. This innovative technology provides clinical teams with a comprehensive set of tools to tailor treatments to individual patient needs. The solution will be showcased at the upcoming ASTRO Annual Meeting, highlighting its capabilities in delivering precise and effective radiotherapy.
Read more →ARAYAccuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025
Accuray Incorporated will host an analyst event on September 29, 2025, during the ASTRO Annual Meeting in San Francisco. The event will feature presentations from global experts discussing adaptive radiotherapy's role in radiation medicine. Both in-person and virtual attendance options are available, with registration required by September 25, 2025.
Read more →ARAYAccuray to Present at JP Morgan 33rd Annual Healthcare Conference
Accuray Incorporated announced its participation in the JP Morgan 33rd Annual Healthcare Conference, scheduled for January 12, 2015. The presentation will be available via a live webcast on the company's Investor Relations page. Accuray specializes in developing innovative tumor treatment solutions in radiation oncology.
Read more →ARAYAccuray to Participate in Brean Capital's 2014 Life Science Conference
Accuray Incorporated will participate in the Brean Capital 2014 Life Science Conference in New York City on November 24, 2014. The company is known for its advanced radiation oncology solutions aimed at improving patient outcomes. This event presents an opportunity for Accuray to showcase its innovations and connect with industry leaders.
Read more →ARAYAccuray Reports Financial Results for First Quarter of Fiscal Year 2015
Accuray Incorporated reported its financial results for the first quarter of fiscal year 2015, with total revenue of $82.4 million, a 7% increase year-over-year. However, gross product orders were disappointing at $58.8 million. The company anticipates stronger order growth in the latter half of the fiscal year, driven by new product releases. Despite revenue growth, the net loss widened to $21.7 million compared to the previous year.
Read more →ARAYAccuray to Report Financial Results for First Quarter Fiscal 2015
Accuray Incorporated will announce its financial results for the first quarter of fiscal 2015 on October 29, 2014. A conference call will be held to discuss these results, with details provided for both dial-in and webcast options. The company continues to emphasize its role in radiation oncology and innovative treatment solutions.
Read more →ARAYAccuray Signs Exclusive Radiation Therapy Solutions Contract With Premier, Inc.
Accuray Incorporated has entered into a three-year exclusive agreement with Premier, Inc. to provide its CyberKnife and TomoTherapy product lines to Premier's extensive network of hospitals and providers. This partnership aims to enhance patient care through innovative radiation therapy solutions and increase Accuray's market visibility. The contract commenced on September 1, 2014.
Read more →ARAYAccuray Reports Financial Results for Fourth Quarter of Fiscal Year 2014 and Introduces Fiscal 2015 Guidance
Accuray Incorporated reported strong financial results for the fourth quarter and fiscal year 2014, with a 20% increase in total revenue and significant growth in gross and net orders. The company achieved a positive adjusted EBITDA of $2.5 million, marking an improvement from the previous year. However, it also reported a net loss of $9.8 million for the quarter, despite overall positive trends.
Read more →ARAYAccuray Incorporated to Present at 2014 Morgan Stanley Global Healthcare Conference
Accuray Incorporated will present at the 2014 Morgan Stanley Global Healthcare Conference on September 8, 2014. The presentation will be available via a live webcast, which will be accessible for 30 days after the event. The company specializes in radiation oncology and aims to improve patient outcomes through its advanced technologies.
Read more →ARAYAccuray to Report Financial Results for Fourth Quarter and Year End Fiscal 2014
Accuray Incorporated will announce its financial results for the fourth quarter and fiscal year ending June 30, 2014, on August 21, 2014. A conference call hosted by CEO Joshua H. Levine and CFO Gregory Lichtwardt will take place at 1:30 p.m. PT. The call will also be available via a live webcast and replay on the company's website.
Read more →ARAYAccuray Incorporated Announces Updated Time of Presentation at Goldman Sachs 35th Annual Healthcare Conference 2014
Accuray Incorporated has announced an updated time for its presentation at the Goldman Sachs 35th Annual Healthcare Conference. The presentation is scheduled for June 12, 2014, at 11:00 a.m. ET. A live webcast will be available on the company's Investor Relations page, with a replay accessible for 30 days post-event.
Read more →ARAYAccuray Incorporated to Present at Goldman Sachs 35th Annual Healthcare Conference 2014
Accuray Incorporated announced its participation in the Goldman Sachs 35th Annual Healthcare Conference, scheduled for June 12, 2014. The presentation will be accessible via a live webcast, which will also be available for replay afterward. This event highlights Accuray's focus on innovative treatment solutions in radiation oncology.
Read more →Competitive Position
How ARAY ranks across every disease it competes inCompetitive Position is a premium feature
See how ARAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial